



# THE WEINBERG GROUP®

## MATTHEW R. WEINBERG

Chief Executive Officer

P +1 202.730.4103

matthew.weinberg@weinberggroup.com

## EDUCATION

- 1983 M.S., Industrial Administration, Tepper School of Business/Graduate School of Industrial Administration, Carnegie-Mellon University, Pittsburgh, PA
- 1979 B.S., Administration and Management Science, double major Economics, Carnegie-Mellon University, Pittsburgh, PA

## EXPERIENCE

Matthew R. Weinberg is Chief Executive Officer at The Weinberg Group. Mr. Weinberg guides all Strategic Issues Management client efforts with an emphasis on providing strategic and operational assistance to technically-oriented entities in areas such as Research and Development (R&D), Regulatory Affairs, and Quality Assurance. His assignments have included strategic development of new products, testimony of the management and economics of scientific enterprises, contract issues and product development.

He is responsible for the growth and success of The Weinberg Group. All activities within the scope of the firm are his responsibility. He drives expansion plans, strategic expansion, acquisitions and personnel development.

In addition, Mr. Weinberg created and leads Building Steps, a non-profit organization providing inner city children in low to middle income families an opportunity to explore career opportunities in science using a program of internships throughout the Baltimore, MD area.

Mr. Weinberg serves on the Boards of the Charles E. Smith Jewish Day School and The Jewish Federation of Greater Washington. In addition, he is a fellow of the Wexner Heritage Foundation. Prior to joining The Weinberg Group, Mr. Weinberg was an assistant vice president with Marine Midland Banks, N.A., and a national account executive with ATT Long Lines.

Mr. Weinberg has a wide range of experience and expertise in the areas of regulatory affairs and technology management. His recent project experience includes:

- Reorganized R&D methods and procedures for a *Fortune* 500 chemical concern.
- Defined new organizational hierarchy and streamlined R&D efforts for a Brazil-based paper pulp supplier.

- Conducted and oversaw a comprehensive on-site audit and inspection of pharmaceutical operations, including development of Standard Operating Procedures, Quality Assurance/Quality Control methods, and management processes.
- Created and managed a multiple-site protocol to meet required Food and Drug Administration consent decree without which the firm could not continue production.
- Managed procedures review to ensure regulatory compliance for an 18-division, multi-national medical device firm.
- Analyzed organization and management of a 2,200-person pharmaceutical research unit leading to a reduction in the time necessary to advance pharmaceuticals through the various development stages.
- Assisted an emerging firm in determining appropriate strategies in pursuing product development of a novel genetic therapy device.
- Completed review of 150 different medical devices and accompanying literature to ensure compliance with FDA Good Manufacturing Practices.

## INVITED PRESENTATIONS

Weinberg MR, Scarola ME. 2010. Claims-based Marketing and the Importance of Good Science. A Webinar presented by The Weinberg Group Inc.; 29 Apr; Washington, DC.

Weinberg MR, Huggard J. 2009. The Politics of Science- What Corporations Can Learn from NGOs. A Webinar presented by The Weinberg Group Inc.; 16 Sep; Washington, DC.

Weinberg MR, Swit MA. 2009. FDA's New Strategy on Enforcement- The Growing Perils of Inadequate Compliance. A Webinar presented by The Weinberg Group Inc.; 9 Sep; Washington, DC.

Weinberg MR, Goljuch ST. 2009. Evaluating Product Risk in a Rapidly Changing Environment. A Webinar presented by The Weinberg Group Inc.; 3 Jun; Washington, DC.

Weinberg MR. 2005. Decreasing Cost by Integrating Compliance into Your Core Business Processes. Speaker at the FDA Regulatory and Compliance Symposium, Managing Risks – From Pipeline to Patient; 24-26 Aug; Cambridge, MA.

Weinberg MR. 2004. Compliance as a Core Business Process. Speaker at the FDANews Quality Systems – Bottom Line Benefits: Advances in Quality Systems and Process Excellence for Pharmaceuticals Conference; May; Philadelphia, PA.



Weinberg MR. 2004. The Regulation of Food Safety and the Use of Traceability/Traceback in the United States and the EU: Convergence or Divergence? Panelist at The European Policy Centre and The Atlantic Council of the United States Food Safety Conference; Mar; in Washington, DC.

Weinberg MR. 2002. GMP Compliance: Better to Start Now. Presentation given at the Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum; Nov; Philadelphia, PA.

Weinberg MR. 2000. Alternative Careers in the Biomedical Sciences. Presentation given at The University of Texas – Houston, Summer Research Program 2000; Jul; Houston, TX.

Frequent presenter and panelist at seminars focusing on Issues in Health Care sponsored by Spencer Stuart. 1996. Irvine, CA.

Weinberg MR. 1996. Science/Law Interface. Presentation given at the Seminar for State and Federal Judges on Science; Oct; Cold Spring Harbor Laboratory, NY.

Weinberg MR. 1996. What Can I Do With A Scientific Graduate Degree? Presentation given at the University of Texas – Houston; May; Houston, TX and the Mayo Clinic and Graduate School "Life After Graduate School" Presentation Series; Oct; in Rochester, MN.

Weinberg MR, Weinberg MS. 1990. Management information system design -- proactive use of in-house information. Paper presented at the Information Management Subsection, Pharmaceutical Manufacturers Association; Apr; Orlando, FL.

Weinberg MR, Weinberg MS, Kusek JZ. 1990. Differences in U.S. and European drug regulation, opportunities for integration, Perestroika and all that. Paper presented at the Research and Development Section, Pharmaceutical Manufacturers Association; Mar; Boca Raton, FL.

Weinberg MR, Weinberg MS. 1989. Differences in U.S. and European drug regulation, opportunities for integration. Paper presented at the International Medical Section, Pharmaceutical Manufacturers Association; Oct; Washington, DC.

Weinberg MR, Weinberg MS. 1989. Differences in U.S. and European drug regulation. Paper presented at the Combined Medical and Regulatory Sections, Pharmaceutical Manufacturers Association; Mar; Laguna Niguel, CA.

## **PUBLICATIONS**

Weinberg MR. 2010. Intelligent compliance. FDLI Update. (6):64-65.

Weinberg MR. 2009. Nanotechnology regulation: could differing views in Europe stifle innovation? FDLI Update. (6):44-46.

Weinberg MR. 2009. Registering orphan drugs in the EU. FDLI Update. (3):50-51.



- Weinberg MR. 2009. TSCA reform in light of global chemicals regulatory change. *FDLI Update*. (1):49-50.
- Weinberg MR. 2008. Requirements for the substantiation of dietary supplement claims. *FDLI Update*. (6):53-55.
- Weinberg MR. 2008. Personalized medicine. *FDLI Update*. (5):61-62.
- Weinberg MR. 2008. Reimbursement in Europe: health technology assessment and what the future may hold. *FDLI Update*. (4):43-44.
- Weinberg MR. 2008. Medical device makers facing challenges with combination products. *FDLI Update*. (3):49-50.
- Weinberg MR. 2008. Regulatory avenues for antibiotic development in the U.S. and EU. *FDLI Update*. (2):52-53.
- Weinberg MR. 2008. Risk assessment playing a bigger role in food safety. *FDLI Update*. (1):54-55.
- Weinberg MR. 2007. The current state of global tissue regulation. *FDLI Update*. (6):45-46.
- Weinberg MR. 2007. Nanotechnology: at risk from poor regulation? *FDLI Update*. (5):49-50.
- Weinberg MR. 2007. New EU law on chemicals is expected to have broad impact. *FDLI Update*. (4):47-48.
- Weinberg MR. 2007. Strides made in global harmonization of drug approval. *FDLI Update*. (3):42-43.
- Weinberg MR. 2007. Critical path to personalized medicine; who will lead the way? *FDLI Update*. (2):43-44.
- Weinberg MR. 2007. RNA interference technology holds out great promise. *FDLI Update*. (1):52-53.
- Weinberg MR. 2006. Protecting privacy of patient information across the U.S. and Europe. *FDLI Update*. (6):47-48.
- Weinberg MR. 2006. EU seeks bigger role in global research arena. *FDLI Update*. (5):47-48.
- Weinberg MR. 2006. The international drug approval process. *FDLI Update*. (4):41-42.
- Weinberg MR. 2006. Qualified health claims. *FDLI Update*. (3).



- Weinberg MR. 2006. Launching new healthcare products in the United States. FDLI Update. (2):58-59.
- Weinberg MR. 2006. Current challenges facing industry in ensuring vaccine availability. FDLI Update. (1):47-48.
- Weinberg MR. 2005. From basic chemicals to consumer products; the implications of nanotechnology. FDLI Update. (6):52-53.
- Weinberg MR. 2005. The issue of trust. FDLI Update. (5):44-45.
- Weinberg MR. 2005. What is next for the regulation of biogenerics? FDLI Update. (4):48-49.
- Weinberg MR. 2005. Generic biologics. FDLI Update. (3):44-45.
- Weinberg MR. 2005. Protecting your business here and abroad. FDLI Update. (2):56-57.
- Weinberg MR. 2005. Regulation by nonregulators. FDLI Update. (1):58-59.
- Weinberg MR. 2004. Direct-to-consumer advertising: U.S. and European perspectives. FDLI Update. (6):49-50.
- Weinberg MR. 2004. Risk communication. FDLI Update. (5):56-57.
- Weinberg MR. 2004. Medical device reimbursement: planning early to meet future challenges. FDLI Update. (4):53-54.
- Weinberg MR. 2004. The salmon debate: food safety, assessing risk, policymaking, and the impact on international food trade. FDLI Update. (3):48-49.
- Weinberg MR. 2004. EU super directive on food packaging: call for action. FDLI Update. (2):48-49.
- Weinberg MR. 2004. Drug counterfeiting- a worldwide concern. FDLI Update. (1):44-45.
- Weinberg MR. 2003. Orphan drug development: gaps and concerns. FDLI Update. (6):54-56.
- Weinberg MR. 2003. Risk-based cGMPs- whose risk is it, anyway? FDLI Update. (5):49-50.
- Weinberg MR. 2003. Product safety update report; a risk management tool for everyone. FDLI Update. (4):52-54.
- Weinberg MR. 2003. Changing views on health and nutrition labeling in Europe. FDLI Update. (3):53-54.
- Weinberg MR. 2003. A strategic approach to generic drugs. FDLI Update. (2):44-45.



Weinberg MR. 2003. Combination products present new challenges. *FDLI Update*. (1):45-46.

Weinberg MR. 2002. Acrylamide in foods – a developing issue. *FDLI Update*. (6):22-23.

Weinberg MR. 2002. Product safety and liability. *FDLI Update*. (6):44-45.

Weinberg MR. 2002. Intellectual property concerns in the EU. *FDLI Update*. (5):44-45.

Weinberg MR. 2002. Global organization and new technologies. *FDLI Update*. (4):44-45.

Weinberg MR. 2002. A global approach to fighting bioterrorism. *FDLI Update*. (3):52-53.

Weinberg MR. 2002. Clinical research productivity. *FDLI Update*. (2):41-42.

Weinberg MR. 2002. Compliance: benefit vs. burden. *FDLI Update*. (1).

Weinberg MR. 2000. Going Over To The Other Side – When Should Drugs Move From Prescription to Over-the-Counter Status? *Legal Times*, June 19.

